

Thomas L Ortel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/571185/publications.pdf>

Version: 2024-02-01

130
papers

9,469
citations

87888

38
h-index

38395

95
g-index

133
all docs

133
docs citations

133
times ranked

10105
citing authors

#	ARTICLE	IF	CITATIONS
1	Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 167-175.	2.1	20
2	Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 767-777.e3.	1.6	2
3	Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2074-2083.	2.4	4
4	New methods facilitated the process of prioritizing questions and health outcomes in guideline development. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 91-104.	5.0	5
5	Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination in United States, December 2020 to August 2021. <i>Annals of Internal Medicine</i> , 2022, 175, 513-522.	3.9	93
6	OUP accepted manuscript. <i>Cardiovascular Research</i> , 2022, , .	3.8	1
7	Introduction to a review series on COVID-19 and the hematologist. <i>Blood</i> , 2022, 140, 163-164.	1.4	1
8	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	3.4	60
9	Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 249-259.	2.1	6
10	Successful Management of Catastrophic Thrombotic Storm in a Young Boy. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, e1132-e1135.	0.6	1
11	Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. <i>Thrombosis Research</i> , 2021, 199, 43-53.	1.7	7
12	Is the use of warfarin becoming obsolete?. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 418-419.	0.8	1
13	Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. <i>Blood</i> , 2021, 138, 293-298.	1.4	87
14	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021, 5, 4721-4726.	5.2	10
15	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 115-127.	5.0	4
16	Anticoagulant Therapy in Patients Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1621.	5.1	11
17	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	5.2	636
18	Meta-analysis fever in the wake of CARAVAGGIO. <i>Thrombosis Research</i> , 2020, 196, 141-142.	1.7	0

#	ARTICLE	IF	CITATIONS
19	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	3.8	69
20	COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. <i>Thrombosis Research</i> , 2020, 196, 483-485.	1.7	31
21	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
22	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	3.8	211
23	Equipose, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID. <i>Circulation</i> , 2020, 142, 2296-2298.	1.6	2
24	Initiation of Emicizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings. <i>Journal of Pharmacy Technology</i> , 2020, 36, 110-113.	1.0	0
25	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2274-2286.	3.8	24
26	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , 2020, 4, 2351-2365.	5.2	26
27	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 500-513.	5.2	10
28	Nanoparticle-Directed Targeting of Clustered PSGL-1 Mitigates Neutrophil-Derived Thrombosis in Antiphospholipid Antibody Syndrome. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
29	COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
30	Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 478-484.	1.3	6
31	Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. <i>Vox Sanguinis</i> , 2019, 114, 374-385.	1.5	16
32	Bad weed: synthetic cannabinoid-associated coagulopathy. <i>Blood</i> , 2019, 133, 902-905.	1.4	19
33	Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches. <i>Applied Clinical Informatics</i> , 2019, 10, 552-562.	1.7	6
34	Risk Factors Associated with 6-Month Recurrent VTE Among Patients in Two Large Population-Based Surveillance Systems. <i>Blood</i> , 2019, 134, 3444-3444.	1.4	0
35	Cancer-Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina. <i>Blood</i> , 2019, 134, 3652-3652.	1.4	0
36	Bleeding and thrombotic complications of pediatric liver transplant. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26955.	1.5	21

#	ARTICLE	IF	CITATIONS
37	Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. <i>Journal of Clinical Apheresis</i> , 2018, 33, 469-479.	1.3	2
38	Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. <i>American Heart Journal</i> , 2018, 195, 108-114.	2.7	28
39	Variants in chondroitin sulfate metabolism genes in thrombotic storm. <i>Thrombosis Research</i> , 2018, 161, 43-51.	1.7	5
40	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	1.7	109
41	Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 591-599.	1.8	19
42	A rare cutaneous manifestation of hemorrhagic bullae to low molecular weight heparin and fondaparinux: report of two cases. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 104-106.	1.3	10
43	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017, 92, 730-738.	4.1	49
44	Associations between positive emotional well-being and stress-induced myocardial ischemia. <i>Journal of Psychosomatic Research</i> , 2017, 93, 14-18.	2.6	11
45	Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. <i>BMJ: British Medical Journal</i> , 2017, 356, j1065.	2.3	174
46	15th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome Report. , 2017, , 307-316.		1
47	Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review. <i>Journal of Arthroplasty</i> , 2016, 31, 524-532.	3.1	65
48	Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. <i>EBioMedicine</i> , 2016, 11, 157-164.	6.1	19
49	Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2016, 63, 1223-1232.	1.6	18
50	A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2016, 18, 101.	2.9	5
51	How I treat catastrophic thrombotic syndromes. <i>Blood</i> , 2015, 126, 1285-1293.	1.4	58
52	Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism. <i>Thrombosis Research</i> , 2015, 136, 535-541.	1.7	30
53	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	27.0	951
54	Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. <i>American Heart Journal</i> , 2015, 169, 496-507.e1.	2.7	15

#	ARTICLE	IF	CITATIONS
55	Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 135, 659-665.	1.7	16
56	Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. <i>Thrombosis Research</i> , 2015, 135, 50-57.	1.7	91
57	Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. <i>Blood</i> , 2015, 126, 427-427.	1.4	12
58	Prothrombin Complex Concentrates and Cardiac Surgery. <i>Blood</i> , 2015, 126, 4712-4712.	1.4	1
59	Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1669-1678.	2.8	78
60	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet</i> , 2014, 383, 880-888.	13.7	425
61	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	5.8	290
62	Challenges and Priorities for Research. <i>Circulation</i> , 2014, 130, 1192-1203.	1.6	28
63	Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency. <i>Thrombosis Research</i> , 2014, 133, 629-633.	1.7	8
64	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	5.8	224
65	Autopsy-Proven Venous Thromboembolism (VTE): Incidence and Characteristics of Patients Correlated with Clinical Management Prior to Death. <i>Blood</i> , 2014, 124, 4257-4257.	1.4	1
66	Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer. <i>Blood</i> , 2014, 124, 4279-4279.	1.4	0
67	Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients. <i>Blood</i> , 2014, 124, 4256-4256.	1.4	0
68	Aspirin Exposure Reveals Novel Genes Associated With Platelet Function and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1267-1276.	2.8	65
69	Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso-Occlusive Pain Crisis In Patients With Sickle Cell Disease. <i>Blood</i> , 2013, 122, 2241-2241.	1.4	8
70	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. <i>Blood</i> , 2013, 122, 36-36.	1.4	3
71	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , 2013, 122, 460-460.	1.4	2
72	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. <i>Blood</i> , 2013, 122, 1126-1126.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 845-853.	2.7	77
74	Prevention of VTE in Orthopedic Surgery Patients. <i>Chest</i> , 2012, 141, e278S-e325S.	0.8	1,723
75	Perioperative management of patients on chronic antithrombotic therapy. <i>Blood</i> , 2012, 120, 4699-4705.	1.4	72
76	Clinical causes and treatment of the thrombotic storm. <i>Expert Review of Hematology</i> , 2012, 5, 653-659.	2.2	29
77	Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2012, 157, 796.	3.9	177
78	Perioperative management of patients on chronic antithrombotic therapy. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 529-535.	2.5	19
79	Antiphospholipid syndrome: Laboratory testing and diagnostic strategies. <i>American Journal of Hematology</i> , 2012, 87, S75-81.	4.1	55
80	Laboratory Diagnosis of the Lupus Anticoagulant. <i>Current Rheumatology Reports</i> , 2012, 14, 64-70.	4.7	15
81	Perioperative management of patients on chronic antithrombotic therapy. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 529-35.	2.5	13
82	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. <i>Blood</i> , 2012, 120, 393-393.	1.4	5
83	High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass. <i>Blood</i> , 2012, 120, 3344-3344.	1.4	0
84	Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.. <i>Blood</i> , 2012, 120, 2203-2203.	1.4	3
85	Hypercoagulability in Pediatric Patients with Sickle Cell Disease and Correlation to Transcranial Doppler and Disease Severity. <i>Blood</i> , 2012, 120, 3221-3221.	1.4	0
86	Thrombotic Storm Revisited: Preliminary Diagnostic Criteria Suggested by the Thrombotic Storm Study Group. <i>American Journal of Medicine</i> , 2011, 124, 290-296.	1.5	45
87	Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. <i>Thrombosis Research</i> , 2011, 128, 536-540.	1.7	39
88	HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery. <i>Blood</i> , 2011, 118, 1159-1159.	1.4	0
89	Referral Patterns and Outcomes for Women with for Recurrent Pregnancy Loss Managed At a Multidisciplinary Thrombosis Program,. <i>Blood</i> , 2011, 118, 4190-4190.	1.4	0
90	Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin for Elective Surger or Procedure - the BRIDGE Trial: Design, Rationale and Clinical Implications. <i>Blood</i> , 2011, 118, 4327-4327.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Acquired thrombotic risk factors in the critical care setting. <i>Critical Care Medicine</i> , 2010, 38, S43-S50.	0.9	33
92	Heparin-Induced Thrombocytopenia. <i>Annual Review of Medicine</i> , 2010, 61, 77-90.	12.2	104
93	Venous Thromboembolism. <i>American Journal of Preventive Medicine</i> , 2010, 38, S495-S501.	3.0	852
94	Heparin Modifies the Immunogenicity of Positively-Charged Proteins.. <i>Blood</i> , 2010, 116, 1435-1435.	1.4	1
95	Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 225-232.	2.5	29
96	Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival. <i>Journal of Clinical Oncology</i> , 2009, 27, 4902-4911.	1.6	197
97	Antiphospholipid Syndrome: Clinical Characteristics of Patients and Affected Family Members From Multiplex Families.. <i>Blood</i> , 2009, 114, 2972-2972.	1.4	0
98	Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA).. <i>Blood</i> , 2009, 114, 2557-2557.	1.4	0
99	Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 14-21.	2.1	31
100	Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2008, 100, 678-684.	3.4	68
101	Prevention and treatment of deep venous thrombosis. <i>Vascular</i> , 2008, 16 Suppl 1, S64-70.	0.9	0
102	Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.. <i>Blood</i> , 2007, 110, 2088-2088.	1.4	3
103	Prediction of Heparin Induced Thrombocytopenia: Validation of an Experience-Based Computer Model.. <i>Blood</i> , 2007, 110, 3226-3226.	1.4	5
104	Whole Blood Gene Expression Profiles Distinguish Patients with Single Prior Venous Thromboembolism from Patients with Multiple Prior Events.. <i>Blood</i> , 2007, 110, 1630-1630.	1.4	0
105	The Reliability of Point-of-Care (POC) Prothrombin Time Testing - A Comparison of CoaguChek XSÂ® INR Measurements with Hospital Laboratory Monitoring.. <i>Blood</i> , 2007, 110, 973-973.	1.4	2
106	Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2006, 355, 809-817.	27.0	560
107	The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 79-83.	2.1	21
108	Clinical Management and Outcomes of Patients with Heparin/Platelet Factor 4 Antibodies: Retrospective Review at a Single Center.. <i>Blood</i> , 2006, 108, 1053-1053.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Gene Expression Patterns Identify Patients with Non-Small Cell Lung Cancer (NSCLC) and Ovarian Cancer Who Are at Increased Risk for Venous Thromboembolism (VTE).. Blood, 2006, 108, 1470-1470.	1.4	0
110	Thrombosis and the Antiphospholipid Syndrome. Hematology American Society of Hematology Education Program, 2005, 2005, 462-468.	2.5	41
111	Clinical implications for patients on antithrombotic therapy while taking supplements. Thrombosis Research, 2005, 117, 75-80.	1.7	1
112	Peripheral Blood Mononuclear Cell Derived Gene Expression Patterns Identify Clinical Phenotypes and Predict Thrombotic Events in Patients with Immune-Mediated Thrombosis.. Blood, 2005, 106, 726-726.	1.4	1
113	Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood, 2004, 104, 2783-2790.	1.4	94
114	A Novel Chemically Induced Fischer F344 Rat Model for Thrombotic Sequelae of Hemolytic Anemias.. Blood, 2004, 104, 3519-3519.	1.4	0
115	Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nature Genetics, 2000, 26, 106-108.	21.4	237
116	Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature, 1999, 402, 434-439.	27.8	258
117	Two Instruments to Determine Activated Partial Thromboplastin Time: Implications for Heparin Monitoring. Pharmacotherapy, 1999, 19, 383-387.	2.6	11
118	Familial antiphospholipid antibody syndrome: Criteria for disease and evidence for autosomal dominant inheritance. Arthritis and Rheumatism, 1999, 42, 318-327.	6.7	68
119	Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis and Rheumatism, 1999, 42, 2250-2252.	6.7	20
120	Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings. Pediatric Radiology, 1998, 28, 597-598.	2.0	4
121	Monitoring oral anticoagulant therapy in patients with lupus anticoagulants. British Journal of Haematology, 1998, 101, 390-391.	2.5	1
122	Inhibitory Anti- Factor V Antibodies Bind to the Factor V C2 Domain and Are Associated With Hemorrhagic Manifestations. Blood, 1998, 91, 4188-4196.	1.4	4
123	Subdural Hematoma and Lupus Anticoagulants. Stroke, 1997, 28, 646-648.	2.0	7
124	Thrombocytopenia in association with a wandering spleen. , 1996, 53, 259-263.		15
125	Effect of Heterologous Factor V Heavy Chain Sequences on the Secretion of Recombinant Human Factor VIII. Thrombosis and Haemostasis, 1996, 75, 036-044.	3.4	3
126	Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. American Journal of Hematology, 1994, 45, 128-135.	4.1	125

#	ARTICLE	IF	CITATIONS
127	Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis. <i>Thrombosis and Haemostasis</i> , 1992, 67, 292-296.	3.4	49
128	Group C Streptococcal Arthritis: Case Report and Review. <i>Clinical Infectious Diseases</i> , 1990, 12, 829-837.	5.8	30
129	Antifibrinolytic therapy in the management of the kasabach merritt syndrome. <i>American Journal of Hematology</i> , 1988, 29, 44-48.	4.1	31
130	Introduction to a review series on pediatric hematology. <i>Blood</i> , 0, , .	1.4	0